Victory Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$251K Sell
26,356
-298,695
-92% -$2.32M ﹤0.01% 2157
2025
Q4
$2.54M Buy
325,051
+265,564
+446% +$1.92M ﹤0.01% 1524
2025
Q3
$452K Sell
59,487
-554
-0.9% -$4.61K ﹤0.01% 2054
2025
Q2
$538K Buy
60,041
+36,256
+152% +$338K ﹤0.01% 2047
2025
Q1
$178K Buy
23,785
+404
+2% +$3.26K ﹤0.01% 2241
2024
Q4
$176K Sell
23,381
-1,468
-6% -$11.1K ﹤0.01% 2262
2024
Q3
$189K Sell
24,849
-737
-3% -$5.6K ﹤0.01% 2237
2024
Q2
$158K Sell
25,586
-558
-2% -$3.08K ﹤0.01% 2239
2024
Q1
$133K Sell
26,144
-698
-3% -$3.92K ﹤0.01% 2265
2023
Q4
$161K Buy
26,842
+6,434
+32% +$37.3K ﹤0.01% 2266
2023
Q3
$144K Buy
20,408
+199
+1% +$1.43K ﹤0.01% 2254
2023
Q2
$142K Sell
20,209
-469
-2% -$3.76K ﹤0.01% 2264
2023
Q1
$172K Sell
20,678
-2,512,906
-99% -$24.2M ﹤0.01% 2277
2022
Q4
$29.1M Sell
2,533,584
-986,647
-28% -$12.3M 0.03% 644
2022
Q3
$44.4M Sell
3,520,231
-1,044,699
-23% -$13.4M 0.05% 503
2022
Q2
$48.3M Buy
4,564,930
+1,011,409
+28% +$10.4M 0.06% 485
2022
Q1
$57.5M Buy
3,553,521
+3,112,255
+705% +$49.9M 0.06% 462
2021
Q4
$6.11M Sell
441,266
-22,908
-5% -$303K 0.01% 1278
2021
Q3
$6.67M Sell
464,174
-189,655
-29% -$2.99M 0.01% 1238
2021
Q2
$10.3M Sell
653,829
-31,655
-5% -$430K 0.01% 1115
2021
Q1
$6.97M Sell
685,484
-241,195
-26% -$2.49M 0.01% 1238
2020
Q4
$6.9M Sell
926,679
-270,876
-23% -$1.4M 0.01% 1164
2020
Q3
$4.11M Buy
1,197,555
+907,591
+313% +$3.89M 0.01% 1236
2020
Q2
$1.38M Buy
289,964
+240,326
+484% +$960K ﹤0.01% 1574
2020
Q1
$100K Buy
+49,638
New +$137K ﹤0.01% 2530
2019
Q4
Sell
-17,281
Closed -$50K 2700
2019
Q3
$50K Buy
+17,281
New +$53.8K ﹤0.01% 2677

Other funds holding BCRX